HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.
<h4>Background</h4>It is unknown if extremely early initiation of antiretroviral therapy (ART) may lead to long-term ART-free HIV remission or cure. As a result, we studied 2 individuals recruited from a pre-exposure prophylaxis (PrEP) program who started prophylactic ART an estimated 10...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7146700700d742c7a0dd1a56e69b9226 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:7146700700d742c7a0dd1a56e69b9226 |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R |
| spellingShingle |
Medicine R Timothy J Henrich Hiroyu Hatano Oliver Bacon Louise E Hogan Rachel Rutishauser Alison Hill Mary F Kearney Elizabeth M Anderson Susan P Buchbinder Stephanie E Cohen Mohamed Abdel-Mohsen Christopher W Pohlmeyer Remi Fromentin Rebecca Hoh Albert Y Liu Joseph M McCune Jonathan Spindler Kelly Metcalf-Pate Kristen S Hobbs Cassandra Thanh Erica A Gibson Daniel R Kuritzkes Robert F Siliciano Richard W Price Douglas D Richman Nicolas Chomont Janet D Siliciano John W Mellors Steven A Yukl Joel N Blankson Teri Liegler Steven G Deeks HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. |
| description |
<h4>Background</h4>It is unknown if extremely early initiation of antiretroviral therapy (ART) may lead to long-term ART-free HIV remission or cure. As a result, we studied 2 individuals recruited from a pre-exposure prophylaxis (PrEP) program who started prophylactic ART an estimated 10 days (Participant A; 54-year-old male) and 12 days (Participant B; 31-year-old male) after infection with peak plasma HIV RNA of 220 copies/mL and 3,343 copies/mL, respectively. Extensive testing of blood and tissue for HIV persistence was performed, and PrEP Participant A underwent analytical treatment interruption (ATI) following 32 weeks of continuous ART.<h4>Methods and findings</h4>Colorectal and lymph node tissues, bone marrow, cerebral spinal fluid (CSF), plasma, and very large numbers of peripheral blood mononuclear cells (PBMCs) were obtained longitudinally from both participants and were studied for HIV persistence in several laboratories using molecular and culture-based detection methods, including a murine viral outgrowth assay (mVOA). Both participants initiated PrEP with tenofovir/emtricitabine during very early Fiebig stage I (detectable plasma HIV-1 RNA, antibody negative) followed by 4-drug ART intensification. Following peak viral loads, both participants experienced full suppression of HIV-1 plasma viremia. Over the following 2 years, no further HIV could be detected in blood or tissue from PrEP Participant A despite extensive sampling from ileum, rectum, lymph nodes, bone marrow, CSF, circulating CD4+ T cell subsets, and plasma. No HIV was detected from tissues obtained from PrEP Participant B, but low-level HIV RNA or DNA was intermittently detected from various CD4+ T cell subsets. Over 500 million CD4+ T cells were assayed from both participants in a humanized mouse outgrowth assay. Three of 8 mice infused with CD4+ T cells from PrEP Participant B developed viremia (50 million input cells/surviving mouse), but only 1 of 10 mice infused with CD4+ T cells from PrEP Participant A (53 million input cells/mouse) experienced very low level viremia (201 copies/mL); sequence confirmation was unsuccessful. PrEP Participant A stopped ART and remained aviremic for 7.4 months, rebounding with HIV RNA of 36 copies/mL that rose to 59,805 copies/mL 6 days later. ART was restarted promptly. Rebound plasma HIV sequences were identical to those obtained during acute infection by single-genome sequencing. Mathematical modeling predicted that the latent reservoir size was approximately 200 cells prior to ATI and that only around 1% of individuals with a similar HIV burden may achieve lifelong ART-free remission. Furthermore, we observed that lymphocytes expressing the tumor marker CD30 increased in frequency weeks to months prior to detectable HIV-1 RNA in plasma. This study was limited by the small sample size, which was a result of the rarity of individuals presenting during hyperacute infection.<h4>Conclusions</h4>We report HIV relapse despite initiation of ART at one of the earliest stages of acute HIV infection possible. Near complete or complete loss of detectable HIV in blood and tissues did not lead to indefinite ART-free HIV remission. However, the small numbers of latently infected cells in individuals treated during hyperacute infection may be associated with prolonged ART-free remission. |
| format |
article |
| author |
Timothy J Henrich Hiroyu Hatano Oliver Bacon Louise E Hogan Rachel Rutishauser Alison Hill Mary F Kearney Elizabeth M Anderson Susan P Buchbinder Stephanie E Cohen Mohamed Abdel-Mohsen Christopher W Pohlmeyer Remi Fromentin Rebecca Hoh Albert Y Liu Joseph M McCune Jonathan Spindler Kelly Metcalf-Pate Kristen S Hobbs Cassandra Thanh Erica A Gibson Daniel R Kuritzkes Robert F Siliciano Richard W Price Douglas D Richman Nicolas Chomont Janet D Siliciano John W Mellors Steven A Yukl Joel N Blankson Teri Liegler Steven G Deeks |
| author_facet |
Timothy J Henrich Hiroyu Hatano Oliver Bacon Louise E Hogan Rachel Rutishauser Alison Hill Mary F Kearney Elizabeth M Anderson Susan P Buchbinder Stephanie E Cohen Mohamed Abdel-Mohsen Christopher W Pohlmeyer Remi Fromentin Rebecca Hoh Albert Y Liu Joseph M McCune Jonathan Spindler Kelly Metcalf-Pate Kristen S Hobbs Cassandra Thanh Erica A Gibson Daniel R Kuritzkes Robert F Siliciano Richard W Price Douglas D Richman Nicolas Chomont Janet D Siliciano John W Mellors Steven A Yukl Joel N Blankson Teri Liegler Steven G Deeks |
| author_sort |
Timothy J Henrich |
| title |
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. |
| title_short |
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. |
| title_full |
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. |
| title_fullStr |
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. |
| title_full_unstemmed |
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. |
| title_sort |
hiv-1 persistence following extremely early initiation of antiretroviral therapy (art) during acute hiv-1 infection: an observational study. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2017 |
| url |
https://doaj.org/article/7146700700d742c7a0dd1a56e69b9226 |
| work_keys_str_mv |
AT timothyjhenrich hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT hiroyuhatano hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT oliverbacon hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT louiseehogan hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT rachelrutishauser hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT alisonhill hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT maryfkearney hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT elizabethmanderson hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT susanpbuchbinder hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT stephanieecohen hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT mohamedabdelmohsen hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT christopherwpohlmeyer hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT remifromentin hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT rebeccahoh hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT albertyliu hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT josephmmccune hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT jonathanspindler hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT kellymetcalfpate hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT kristenshobbs hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT cassandrathanh hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT ericaagibson hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT danielrkuritzkes hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT robertfsiliciano hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT richardwprice hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT douglasdrichman hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT nicolaschomont hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT janetdsiliciano hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT johnwmellors hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT stevenayukl hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT joelnblankson hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT teriliegler hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy AT stevengdeeks hiv1persistencefollowingextremelyearlyinitiationofantiretroviraltherapyartduringacutehiv1infectionanobservationalstudy |
| _version_ |
1718375846339674112 |
| spelling |
oai:doaj.org-article:7146700700d742c7a0dd1a56e69b92262021-12-02T19:56:00ZHIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.1549-12771549-167610.1371/journal.pmed.1002417https://doaj.org/article/7146700700d742c7a0dd1a56e69b92262017-11-01T00:00:00Zhttps://doi.org/10.1371/journal.pmed.1002417https://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4>It is unknown if extremely early initiation of antiretroviral therapy (ART) may lead to long-term ART-free HIV remission or cure. As a result, we studied 2 individuals recruited from a pre-exposure prophylaxis (PrEP) program who started prophylactic ART an estimated 10 days (Participant A; 54-year-old male) and 12 days (Participant B; 31-year-old male) after infection with peak plasma HIV RNA of 220 copies/mL and 3,343 copies/mL, respectively. Extensive testing of blood and tissue for HIV persistence was performed, and PrEP Participant A underwent analytical treatment interruption (ATI) following 32 weeks of continuous ART.<h4>Methods and findings</h4>Colorectal and lymph node tissues, bone marrow, cerebral spinal fluid (CSF), plasma, and very large numbers of peripheral blood mononuclear cells (PBMCs) were obtained longitudinally from both participants and were studied for HIV persistence in several laboratories using molecular and culture-based detection methods, including a murine viral outgrowth assay (mVOA). Both participants initiated PrEP with tenofovir/emtricitabine during very early Fiebig stage I (detectable plasma HIV-1 RNA, antibody negative) followed by 4-drug ART intensification. Following peak viral loads, both participants experienced full suppression of HIV-1 plasma viremia. Over the following 2 years, no further HIV could be detected in blood or tissue from PrEP Participant A despite extensive sampling from ileum, rectum, lymph nodes, bone marrow, CSF, circulating CD4+ T cell subsets, and plasma. No HIV was detected from tissues obtained from PrEP Participant B, but low-level HIV RNA or DNA was intermittently detected from various CD4+ T cell subsets. Over 500 million CD4+ T cells were assayed from both participants in a humanized mouse outgrowth assay. Three of 8 mice infused with CD4+ T cells from PrEP Participant B developed viremia (50 million input cells/surviving mouse), but only 1 of 10 mice infused with CD4+ T cells from PrEP Participant A (53 million input cells/mouse) experienced very low level viremia (201 copies/mL); sequence confirmation was unsuccessful. PrEP Participant A stopped ART and remained aviremic for 7.4 months, rebounding with HIV RNA of 36 copies/mL that rose to 59,805 copies/mL 6 days later. ART was restarted promptly. Rebound plasma HIV sequences were identical to those obtained during acute infection by single-genome sequencing. Mathematical modeling predicted that the latent reservoir size was approximately 200 cells prior to ATI and that only around 1% of individuals with a similar HIV burden may achieve lifelong ART-free remission. Furthermore, we observed that lymphocytes expressing the tumor marker CD30 increased in frequency weeks to months prior to detectable HIV-1 RNA in plasma. This study was limited by the small sample size, which was a result of the rarity of individuals presenting during hyperacute infection.<h4>Conclusions</h4>We report HIV relapse despite initiation of ART at one of the earliest stages of acute HIV infection possible. Near complete or complete loss of detectable HIV in blood and tissues did not lead to indefinite ART-free HIV remission. However, the small numbers of latently infected cells in individuals treated during hyperacute infection may be associated with prolonged ART-free remission.Timothy J HenrichHiroyu HatanoOliver BaconLouise E HoganRachel RutishauserAlison HillMary F KearneyElizabeth M AndersonSusan P BuchbinderStephanie E CohenMohamed Abdel-MohsenChristopher W PohlmeyerRemi FromentinRebecca HohAlbert Y LiuJoseph M McCuneJonathan SpindlerKelly Metcalf-PateKristen S HobbsCassandra ThanhErica A GibsonDaniel R KuritzkesRobert F SilicianoRichard W PriceDouglas D RichmanNicolas ChomontJanet D SilicianoJohn W MellorsSteven A YuklJoel N BlanksonTeri LieglerSteven G DeeksPublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 14, Iss 11, p e1002417 (2017) |